START CENTER FOR CANCER CARE OFFERS ROUTINE, COMPREHENSIVE GENOMIC PROFILING OF PATIENTS’ TUMORS. START is the first center in South Texas to make this sophisticated testing routinely available to patients and other oncologists. Testing will direct physicians in the selection of targeted therapies of both conventional and investigational drugs.
The START Center for Cancer Care has begun offering cancer patients routine comprehensive genomic profiling of their tumors using a unique combination of technologies -- array CGH and oncogene mutation anylisis. START is the only center in South Texas to make this molecular diagnostic testing of tumor tissue routinely available to patients, and the first to make both technologies available to any oncology patient as a clinical test. Patients do not need to be in treatment at START to have their tumors tested.Genomic profiling represents a new tool in treating cancer and clinicians and researchers alike believe that it will enable them to better direct patients to targeted therapies of both conventional and investigational drugs. It is considered a major step in the delivery of personalized medicine. The new service will be coordinated through the new division, GenomeConsult at The START Center, and will be operated under the supervision of Shelly Gunn M.D., Ph.D. , a board certified clinical pathologist. The information her team provides will give oncologists important otherwise unavailable data concerning the specific mutations and unique pattern of changes detectable in each patient's tumor.
No comments:
Post a Comment